Terms ending in 2028
Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,303,953 | Antibody Molecules Which Bind IL-17A and IL-17F In force · High confidence | Ucb Biopharma SPRL | In force | High confidence | |
| US 9,045,537 | Antibodies Specific to IL-17A and IL-17F In force · Medium confidence | Ucb Biopharma SPRL | In force | Medium confidence | |
| US 8,088,398 | Pharmaceutical Compositions Comprising Fesoterodine In force · Medium confidence | Ucb Pharma GmbH | In force | Medium confidence | |
| US 8,784,823 | Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 9,321,840 | Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 8,338,592 | Fused Thiazole Derivatives as Kinase Inhibitors In force · High confidence | Ucb Biopharma SRL | In force | High confidence | |
| US 7,863,316 | Extended Release Formulation of Levetiracetam In force · High confidence | Ucb Pharma S.A. | In force | High confidence | |
| US 7,858,122 | Extended Release Formulation of Levetiracetam In force · High confidence | Ucb Pharma S.A. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.